Pscilly

Sheppard Pratt trial reports 12-week reductions in suicidal thoughts

By · Published · Updated

A clinical trial conducted at Sheppard Pratt reported that participants with chronic suicidal ideation and treatment-resistant depression experienced reductions in suicidal thoughts after psilocybin-assisted therapy. The findings appeared in the June 2026 issue of the Journal of Clinical Psychiatry, according to Sheppard Pratt’s May 28 announcement. The open-label study followed 20 adults with major depression and long-running suicidal thoughts for whom two or more earlier antidepressants had not worked. Participants received one 25-milligram dose of COMP360 psilocybin in a program that included preparation, supervised administration and integration sessions. Researchers followed them for 12 weeks. According to the report, suicidal ideation scores had fallen significantly by one week after treatment, and the improvement continued through the follow-up period. By the 12-week mark, 70% said such thoughts were minimal or gone. The study also reported reductions in depressive symptoms at each post-treatment assessment, and no serious adverse events during the trial. The researchers described the results as early evidence, while noting that larger randomized controlled trials are needed to assess the treatment’s effectiveness, durability and long-term safety. It ran with FDA investigational-drug clearance and sign-off from the hospital's own ethics review board. For mushroom readers, the study adds to research on psilocybin in a population the announcement says is often excluded from psychedelic trials, but its small, open-label design means the findings are preliminary.

Published
May 28, 2026
Place
Towson, MD
Source
sheppardpratt.org

Nearby